These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
221 related articles for article (PubMed ID: 35676709)
21. Progressive fibrosing interstitial lung diseases: A new concept and indication of nintedanib. Makino S Mod Rheumatol; 2021 Jan; 31(1):13-19. PubMed ID: 32964766 [TBL] [Abstract][Full Text] [Related]
22. Incidence and Prognostic Significance of Hypoxemia in Fibrotic Interstitial Lung Disease: An International Cohort Study. Khor YH; Gutman L; Abu Hussein N; Johannson KA; Glaspole IN; Guler SA; Funke-Chambour M; Geiser T; Goh NSL; Ryerson CJ Chest; 2021 Sep; 160(3):994-1005. PubMed ID: 33905679 [TBL] [Abstract][Full Text] [Related]
23. CXCR4 Jaffar J; Griffiths K; Oveissi S; Duan M; Foley M; Glaspole I; Symons K; Organ L; Westall G Respir Res; 2020 Aug; 21(1):221. PubMed ID: 32843095 [TBL] [Abstract][Full Text] [Related]
24. Comparison of the antifibrotic effects of the pan-histone deacetylase-inhibitor panobinostat versus the IPF-drug pirfenidone in fibroblasts from patients with idiopathic pulmonary fibrosis. Korfei M; Stelmaszek D; MacKenzie B; Skwarna S; Chillappagari S; Bach AC; Ruppert C; Saito S; Mahavadi P; Klepetko W; Fink L; Seeger W; Lasky JA; Pullamsetti SS; Krämer OH; Guenther A PLoS One; 2018; 13(11):e0207915. PubMed ID: 30481203 [TBL] [Abstract][Full Text] [Related]
26. Gremlin-1 for the Differential Diagnosis of Idiopathic Pulmonary Fibrosis Versus Other Interstitial Lung Diseases: A Clinical and Pathophysiological Analysis. Aoshima Y; Enomoto Y; Muto S; Meguro S; Kawasaki H; Kosugi I; Fujisawa T; Enomoto N; Inui N; Nakamura Y; Suda T; Iwashita T Lung; 2021 Jun; 199(3):289-298. PubMed ID: 33770226 [TBL] [Abstract][Full Text] [Related]
27. Diagnostic and Therapeutic Developments in Progressive Pulmonary Fibrosis. Molina-Molina M; Buendia-Roldan I; Castillo D; Caro F; Valenzuela C; Selman M Arch Bronconeumol; 2022 May; 58(5):418-424. PubMed ID: 35312511 [TBL] [Abstract][Full Text] [Related]
28. Clinical profile of unclassifiable interstitial lung disease: Comparison with chronic fibrosing idiopathic interstitial pneumonias. Traila D; Oancea C; Tudorache E; Mladinescu OF; Timar B; Tudorache V J Int Med Res; 2018 Jan; 46(1):448-456. PubMed ID: 28758849 [TBL] [Abstract][Full Text] [Related]
29. Cough is less common and less severe in systemic sclerosis-associated interstitial lung disease compared to other fibrotic interstitial lung diseases. Cheng JZ; Wilcox PG; Glaspole I; Corte TJ; Murphy D; Hague CJ; Ryerson CJ Respirology; 2017 Nov; 22(8):1592-1597. PubMed ID: 28544079 [TBL] [Abstract][Full Text] [Related]
30. Review series: Aspects of interstitial lung disease: connective tissue disease-associated interstitial lung disease: how does it differ from IPF? How should the clinical approach differ? de Lauretis A; Veeraraghavan S; Renzoni E Chron Respir Dis; 2011; 8(1):53-82. PubMed ID: 21339375 [TBL] [Abstract][Full Text] [Related]
31. Exposure-safety analyses of nintedanib in patients with chronic fibrosing interstitial lung disease. Schmid U; Weber B; Sarr C; Freiwald M BMC Pulm Med; 2021 Jul; 21(1):244. PubMed ID: 34289823 [TBL] [Abstract][Full Text] [Related]
32. Pleiotropic effect of the proton pump inhibitor esomeprazole leading to suppression of lung inflammation and fibrosis. Ghebremariam YT; Cooke JP; Gerhart W; Griego C; Brower JB; Doyle-Eisele M; Moeller BC; Zhou Q; Ho L; de Andrade J; Raghu G; Peterson L; Rivera A; Rosen GD J Transl Med; 2015 Aug; 13():249. PubMed ID: 26231702 [TBL] [Abstract][Full Text] [Related]
33. The Bleomycin Model of Pulmonary Fibrosis. Liu T; De Los Santos FG; Phan SH Methods Mol Biol; 2017; 1627():27-42. PubMed ID: 28836192 [TBL] [Abstract][Full Text] [Related]
34. Olodaterol shows anti-fibrotic efficacy in in vitro and in vivo models of pulmonary fibrosis. Herrmann FE; Wollin L; Wirth J; Gantner F; Lämmle B; Wex E Br J Pharmacol; 2017 Nov; 174(21):3848-3864. PubMed ID: 28810065 [TBL] [Abstract][Full Text] [Related]